Onyx®: a unique neuroembolic agent

Rupture of a cerebral arteriovenous malformation can result in devastating hemorrhage with a possibility of serious neurological injury or death. Endovascular embolization is an important adjunct in the treatment of cerebral arteriovenous malformations, and in a small number of cases may provide definitive treatment. Currently available embolic agents have several shortcomings, including the possibility of recanalization, adhesiveness to the endovascular microcatheter and suboptimal handling at the time of surgical resection. Onyx is an ethylene vinyl alcohol copolymer dissolved in dimethyl sulfoxide that was approved by the US FDA in July 2005 as an embolic agent for brain arteriovenous malformations. Although long-term follow-up is limited, this agent appears to offer several advantages over the other available embolic agents for the endovascular management of arteriovenous malformations and other vascular lesions.

Endovascular Treatment of Cerebral Arteriovenous Malformations

The modern management of cerebral arteriovenous malformations (AVMs) is based on three therapeutic modalities: microneurosurgery, endovascular embolization, and stereotactic radiosurgery. Embolization facilitates subsequent radiosurgery by reducing the volume of the nidus, prepares the resection of surgically accessible AVMs, and immediately addresses the risks related to associated intra/extranidal aneurysms and arteriovenous fistulas. We discuss in this article the current state of AVM endovascular therapy.